Canadian drug-device developer Interface raises funds
This article was originally published in Clinica
Executive Summary
Interface Biologics, a spin-out from the University of Toronto, Canada, has closed its first venture capital financing, raising Can$10m (US$8.2m). It will use the proceeds to fund ongoing biomaterial development programmes, and to support corporate partnerships.